Skip to content

Precision HD-tACS for Enhancing Sensory Experience in Schizophrenia

Precision HD-tACS-Based Therapy for the Qualitative and Phenomenological Enhancement of Sensory Experiences in Schizophrenia

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07632261
Acronym
TherACles
Enrollment
80
Registered
2026-06-08
Start date
2026-06-15
Completion date
2030-05-01
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SCHIZOPHRENIA 1 (Disorder), Sensory Perceptual Characteristics

Keywords

perceptual binding, sensory perception, transcranial stimulation, tACS

Brief summary

To ensure unified sensory perception, the brain must link information from different senses across time and space. This unification of perception often referred to as a perceptual "binding constraint" is a prerequisite for any organized perception. Patients with schizophrenia exhibit deficits in the spatiotemporal binding of sensory information . Electroencephalography (EEG) studies highlight the role of delta-theta oscillatory dynamics (2-8 Hz) in neuronal entrainment processes underlying spatiotemporal binding, which enables the formation of a coherent and organized perceptual representation . These same dynamics are disrupted in schizophrenia . In tasks assessing perceptual binding, such alterations manifest as widened temporal binding windows, reflecting impaired temporal structuring of visual events. Physiologically, these disruptions may stem from impaired feedback mechanisms within the cortico-cerebello-thalamo-cortical (CCTC) loop. Schizophrenia patients also exhibit functional and structural deficits in the pulvinar and frontal cortex, key nodes of the CCTC loop . Recent technical advances in transcranial neurostimulation have reinforced its potential as a therapeutic tool. High-definition transcranial alternating current stimulation (HD-tACS) now enables individualized modulation of pre-identified neural networks , including targeted interventions for schizophrenia . Based on a personalized stimulation protocol, this research project proposes precision HD-tACS therapy, tailored for each patient according to their delta-theta peak frequency measured via EEG and the optimal functional stimulation site identified with functional MRI (fMRI). Stimulation will be applied functionally, i.e., while the patient performs a cognitive task. Structural connectivity alterations have been observed in fronto-thalamic, thalamo-cingulate, and cortico-cerebellar pathways in schizophrenia, potentially underpinning temporal and spatial binding deficits. Assessing the integrity of the CCTC loop with diffusion tensor imaging (DTI) will allow quantification of fiber coherence and white matter density connecting cortical and subcortical regions within this network.To evaluate both baseline perceptual deficits and the potential improvements induced by stimulation, a control group of healthy participants will be included.

Interventions

DEVICETranscranial neurostimulation

Active HD-tACS

DEVICESham Transcranial neurostimulation

Sham HD-tACS

Sponsors

Hôpital le Vinatier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Intervention model description

40 patient participants and 40 healthy controls

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

for control group and patient: * Be aged 18 to 65 years inclusive. * Have read and understood the study information sheet. * Be affiliated with a social security system or be a beneficiary. * Have normal or corrected-to-normal vision (glasses or contact lenses).

Exclusion criteria

for control group : * Any contraindication to tACS, e.g., cardiac pacemaker or other devices that could interfere with the electric field. * Any contraindication to MRI, e.g., neurological stimulator, pacemaker, cardiac defibrillator, cardiac or vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metallic fragments in the eyes, cochlear implants, severe claustrophobia. (A standardized MRI screening questionnaire will be provided.) * Pregnancy or breastfeeding. (Pregnancy status will be verified with a test on the day of the exam.) * Legal incapacity (under guardianship, conservatorship, or judicial/administrative detention) or inability to provide informed consent. * Major psychiatric disorders (excluding tobacco use disorder). * Neurological disorders. * Severe somatic disorders that could interfere with participation. * Uncorrected visual impairments. * Recent consumption of substances likely to alter brain activity (alcohol, drugs, etc.). * Presence of any psychiatric disorder. * Under legal protection (guardianship or conservatorship).

Design outcomes

Primary

MeasureTime frameDescription
Point of subjective equality(PSE)Day1: pre-intervention From 2 days to 20 days maximum: intervention and post-interventionThis outcome measures perceptual bias by estimating the Point of Subjective Equality (PSE), defined as the stimulus intensity at which participants perceive two stimuli as equal with 50% probability. The PSE is extracted from a fitted psychometric function and compared between PRE and POST phases. Unit: same as stimulus dimension (e.g., ms, Hz, or intensity level). No fixed min/max value

Secondary

MeasureTime frameDescription
Functional connectivity, assessed via the phase-locking value (PLV).Day1: pre-intervention From 2 days to 20 days maximum: post-interventionElectrophysiological data analysis will focus on signal coherence, measured by the phase-locking value (PLV). The PLV quantifies over time the phase-locking differences (Δφ) between different topographical points. When EEG activity is entrained by an external stimulation, signal coherence increases, and Δφ remains consistent across trials. Conversely, if there is no relationship between the signals recorded at different scalp locations, Δφ will vary randomly across trials. Δφ values will be compared between the PRE and POST stimulation phases. Index between 0 and 1

Contacts

CONTACTLydie SARTELET
lydie.sartelet@ch-le-vinatier.fr+334 37 91 55 31
PRINCIPAL_INVESTIGATORWilliam VALLET, PhD

Le Vinatier Psychiatrie Universitaire Lyon Métropole

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026